Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ETCompany ParticipantsJustine Koenigsberg - Vice President ...

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...

JAMA study confirms that vaccines measurably alter menstrual cycle timing, offering direct evidence of neuroendocrine effects ...

United Kingdom Centre of Membrane Proteins and Receptors, University of Birmingham and Nottingham, The Midlands NG7 2UH, United Kingdom ...

However, the male population showed higher positive signal intensities than the female ... evidence suggests that tocilizumab (an IL-6 receptor antagonist) exhibits significant therapeutic potential ...

Methods: The research analyzed specific genetic variations—TNF-α −308 G/A, TNF-α −857 C/T, TNF-α −238G/A, IL1B-3953 C/T, and IL1RN −2018T/C SNPs—within 212 migraine patients and 210 healthy controls.

Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. 4,5 Here, we review ...

The evidence supporting this mechanism is incomplete, with additional work needed to clarify SHP-1's role, the contribution of Fc receptor crosslinking ... impact of DuoHexaBody-CD37 on direct ...

J Neuroinflammation © 2008 McCoy and Tansey; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons ...

TNF receptor 1 (TNFR1) is expressed in most cell ... selective targeting of TNFR1-mediated signaling while sparing TNFR2 activation may lessen adverse effects of anti-TNF therapies in the CNS.